HASBROUCK HEIGHTS, N.J., October 4 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) is pleased to announce the publication of a
peer-reviewed report on the successful results of a multi-center double blind
independent clinical study of the Company's urinary AlzheimAlert(TM) test in
the Journal of the American Medical Directors Association (www.jamda.com). The
newly published independent peer-review study from 8 prestigious centers
across the U.S. found the level of accuracy of the Alzheimalert(TM) urine test
to be over 90%. The study was double-blind and involved expert assessments and
state of the art clinical correlations and continued evaluations.
